



Full Length Article

Aging and lineage allocation changes of bone marrow skeletal (stromal) stem cells

Jan O. Nehlin^{a,b,*}, Abbas Jafari^{a,c}, Michaela Tencerova^{a,d}, Moustapha Kassem^{a,c,e,**}^a The Molecular Endocrinology & Stem Cell Research Unit (KMEB), Department of Endocrinology, Odense University Hospital & University of Southern Denmark, Odense, Denmark^b Clinical Research Center, Copenhagen University Hospital, Hvidovre, Denmark^c Department of Cellular and Molecular Medicine, The Novo Nordisk Foundation Center for Stem Cell Biology (DanStem), Panum Institute, University of Copenhagen, Copenhagen, Denmark^d Danish Diabetes Academy, Novo Nordisk Foundation, Odense, Denmark^e Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia

ARTICLE INFO

Keywords:

Bone marrow stromal stem cells
Senescence
Aging
Adiposity
Signaling pathways

ABSTRACT

Aging is associated with decreased bone mass and accumulation of bone marrow adipocytes. Both bone forming osteoblastic cells and bone marrow adipocytes are derived from a stem cell population within the bone marrow stroma called bone marrow stromal (skeletal or mesenchymal) stem cells (BMSC). In the present review, we provide an overview, based on the current literature, regarding the physiological aging processes that cause changes in BMSC lineage allocation, enhancement of adipocyte and defective osteoblast differentiation, leading to gradual exhaustion of stem cell regenerative potential and defects in bone tissue homeostasis and metabolism. We discuss strategies to preserve the “youthful” state of BMSC, to reduce bone marrow age-associated adiposity, and to counteract the overall negative effects of aging on bone tissues with the aim of decreasing bone fragility and risk of fractures.

1. Introduction

Bone is a dynamic tissue that is constantly remodeled and regenerated by the balancing act of osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Balance between bone formation and resorption maintains the skeletal integrity until pathological processes, commonly age-associated, disrupt this balance leading to bone fragility and increased risk for fracture manifesting as the osteoporotic syndrome [1]. Histological studies of bone biopsies of aged and osteoporotic patients revealed an inverse relationship between decreased bone mass and increased marrow adipose tissue (MAT)

formation suggesting a possible causal patho-physiological mechanism [2,3].

Bone marrow stromal stem cells (BMSC) (also known as skeletal or mesenchymal stem cells) constitute a specific adult stem cell population within the bone marrow (BM) compartment that is required for bone tissue remodeling and regeneration. BMSC differentiate into mainly the mesoderm-type cells: osteoblasts and adipocytes [4]. One hypothesis that has been examined in bone biology during the recent years, to explain the presence of an inverse relationship between age-related decreased in bone mass and increase MAT, is the increased commitment of BMSC to bone marrow adipocytes (BMA) and impaired osteoblast

Abbreviations: ALP, alkaline phosphatase; BAT, brown adipose tissue; BM, bone marrow; BMSC, bone marrow stromal stem cells; BMA, bone marrow adipocyte; BMD, bone mineral density; C/EBP, CCAAT enhancer binding proteins; CNS, central nervous system; Col1, collagen type I; CFU-F, colony forming unit-fibroblast; Dlk1, Delta-like 1; DPP4, Dipeptidyl-peptidase-4; Dlx5, Distal-less homeobox 5 gene; E, estrogen; FGF21, Fibroblast growth factor 21; FOXP1, Forkhead box P1; GLP-1, Glucagon-like-peptide-1; GC, glucocorticoids; GDF, growth differentiation factors; kDa, kilodaltons; hBMSC, human bone marrow stromal stem cells; IGF1, Insulin-like growth factor 1; IGF1R, Insulin-like growth factor-binding protein; Lgmn, legumain; MRI, magnetic resonance imaging; MAT, marrow adipose tissue; OC, osteocalcin; OVX, ovariectomized; PPAR γ , peroxisome proliferator-activated receptor gamma; PTH, parathyroid hormone; RANKL, receptor activator of nuclear factor kB ligand; ROS, reactive oxygen species; Runx2, Runt-related transcription factor 2; SOST, sclerostin; SrRN, Strontium Ranelate; sFRP, Secreted frizzled-related protein 1; TH, thyroid hormone; TNF α , Tumor Necrosis Factor-alpha; TGF β , transforming growth factor-beta; WAT, white adipose tissue

* Correspondence to: J.O. Nehlin, Clinical Research Center, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark.

** Correspondence to: M. Kassem, The Molecular Endocrinology & Stem Cell Research Unit (KMEB), Department of Endocrinology, Odense University Hospital, Odense, Denmark.

E-mail addresses: jan.nehlin@regionh.dk (J.O. Nehlin), mkassem@health.sdu.dk (M. Kassem).

<https://doi.org/10.1016/j.bone.2019.03.041>

Received 16 January 2019; Received in revised form 30 March 2019; Accepted 31 March 2019

Available online 01 April 2019

8756-3282/ © 2019 Elsevier Inc. All rights reserved.

differentiation [5,6].

The aim of this review is to present an analysis of the phenotypic and molecular characteristics of the age-related changes in BMSC and possible molecular causes mediated by age-related changes in local and systemic factors known to regulated BMSC biological functions. We will also discuss possible interventions to prevent these deleterious effects on BMSC biology, bone formation and bone fragility. We base our discussion on the concept that physiological aging leads to senescence-associated changes in BMSC as the general underlying mechanism for changes in lineage allocation and differentiation. In addition, we present concepts related to cellular senescence as examined in the biogerontology literature and that have previously been employed to discuss mechanisms of osteoblastic cell senescence [5,6].

2. Phenotypic age-related changes in bone marrow tissue

The site of generation of BMSC is the bone marrow located between bone trabeculae of cancellous (spongy) bone of either axial or peripheral skeleton and can be phenotypically classified as either red marrow, mainly filled with hematopoietic cells, and yellow marrow, characterized by increased formation of adipocytes (reviewed in [7]). Changes in marrow composition and proportion of MAT vary with gender, age, location within the bone, lifestyle, exposure to environmental factors [3,8].

Studies of the qualitative changes in the marrow in humans have been reported since 1882, when Ernst Neumann recognized that with age, there is a trabecular bone atrophy and that most of the bone marrow in the axial skeleton consists of adipose tissue that does not take part in hematopoiesis. These findings were corroborated by many investigators [2,9–11].

More recent studies using alternative methodologies confirmed these initial histomorphometric findings in aged and osteoporotic patients [12,13]. Along gender lines, changes in marrow including a sharp increase in MAT content is observed in female subjects between 55 and 65 years of age while in male subjects the increase is much more gradual but steady, resulting in higher marrow fat content in females older than 60 years compared to males [13].

3. Mechanisms of age-associated changes in BMSC lineage allocation and differentiation

The underlying cellular and molecular mechanisms of age-related changes in bone and MAT are not fully characterized. However, these mechanisms can be classified as intrinsic BMSC age-associated changes (A) or age-related changes in the bone microenvironment (B).

(A) Age-related intrinsic changes in BMSC

BMSC are identified by their clonogenic growth capacity, known as colony forming unit-fibroblast (CFU-F) and their ability to differentiate when cultured *in vitro*. The CFU-F assay has been employed as a surrogate marker of the number of BMSC *in vivo*. The number of CFU-F decreases with age in mice and rats [22,23] but human studies revealed lack of an age-related effect when donor age is between 20 and 80 (reviewed in [5,24]). More recent studies employed surface markers to define BMSC and to enumerate them. Murine BMSC defined by CD45⁻CD31⁻Sca1⁺CD24⁺ exhibited a reduction in number with age, when comparing 2 months- vs. 15 months-old mice [25]. Likewise, a decline in bone mass with age in 20–24 months old mice was reported to be the result of intrinsic defects in Osx1⁺ osteoprogenitor cells, leading to decreased osteoblast numbers and increased support of osteoclast formation [21]. In a human study, a certain decrease with age in the number of CD271⁺SSEA-4⁺ BMSC was reported, but bone marrow samples were not representative of healthy aging as they were collected from femur heads of patients suffering femoral osteonecrosis or osteoarthritis [26]. Thus, differences in bone marrow preparation

methods, source of the bone marrow utilized, or definition of CFU-F or BMSC population can explain the reported discrepant results (reviewed in [5,24]).

To determine the existence of intrinsic age-related changes in BMSC that lead to changes in BMSC lineage allocation, several models have been employed. Studies in senescent accelerated mouse model (SAMP-6) [27] and in normal aged mice [28], showed increased adipocyte differentiation (increased expression of adipocyte markers PPAR- γ 2 and fatty acid binding protein aP2) along with a reduction in osteoblastogenesis (decreased expression of osteoblastic markers Runt-related transcription factor 2 (Runx2), Distal-less homeobox 5 gene (Dlx5), collagen and osteocalcin) in BMSC cultures [28]. On the other hand, differentiation capacity of murine CD45⁻CD31⁻Sca1⁺ BMSC was not altered by age [25] nor did plastic-adherent human bone marrow-derived stromal stem cells (hBMSC) [16,29]. Human CD271⁺SSEA-4⁺ BMSC obtained from elderly patients showed evidence of cellular senescence, as indicated by their low growth potential, high senescence-associated beta-galactosidase activity, and elevated p16 and p21 CDK inhibitor levels as well as weak osteogenic differentiation but higher adipogenic differentiation capacity [26]. Interestingly, in some studies, cultured hBMSC and adipose tissue-derived MSC have been reported to be refractory to differentiation when they become senescent [30,31]. One of the consistent findings regarding intrinsic defects of hBMSC, is the presence of reduced proliferative potential of hBMSC in long term cultures [32].

A hallmark of aging-associated pathologies is the presence of senescent cells in tissues [14]. In the bone microenvironment, subset of cells of various lineages become senescent in chronologically aged subjects, especially myeloid cells and osteocytes, but also a Lin⁻/Leptin receptor⁺ population that contains most bone-marrow-derived osteoblast progenitors. All senescent cell subsets develop a senescence-associated secretory phenotype (SASP) that is higher with aging in bone biopsies that may mediate age-related bone loss in mice and humans [15].

Aging is associated with many cellular and molecular changes leading to cellular senescence that contribute to the aging phenotype. General mechanisms underlying the bone aging phenotype have been shown including dysfunctional telomeres, age-related increased in DNA damage and impaired DNA repair mechanisms [15–21].

3.1. Age-related changes in intracellular signaling pathways and transcriptional factors

Differentiation of BMSC into osteoblastic or adipocytic cells is regulated by number of genetic signaling pathways that converge on lineage-specific transcriptional factors and that exhibit age-related changes [33](Fig. 1 and Table 1).

3.2. Wnt signaling

Two independent Wnt signaling pathways—the canonical Wnt/ β -catenin pathway and the non-canonical Wnt pathway—induce osteoblastogenesis and suppress adipogenesis [34]. On the other hand, excessive activation of the Wnt/ β -catenin signaling pathway, resulted in activation of the DNA damage response and the p53/p21 pathway inducing the aging of BMSC [35].

3.3. Peroxisome proliferated-activated receptor gamma (PPAR γ)

The most characterized transcription factor and a key regulator of adipogenesis is PPAR γ , that belongs to a nuclear receptor superfamily activated by lipophilic ligands. The activation of PPAR γ is necessary and sufficient for adipocyte differentiation and, also, required for maintenance of a differentiated state in BMSC [36,37]. Inhibition of PPAR γ *in vitro* impairs adipogenesis, while enhancing osteoblast differentiation in BMSC. In mice, PPAR γ deficiency leads to impaired




Fig. 1. Scheme illustrating the intrinsic and extrinsic factors influencing BMA and the possible functional roles of BMA during aging.

Table 1

List of selected regulatory factors promoting adipocyte differentiation in the bone marrow.

Name	Symbol	Category	References
Peroxisome proliferated-activated receptor γ	PPAR γ	Transcription factor	[36,37,43]
CCAAT enhancer binding proteins	C/EBP α / β / γ / δ	Transcription factors	[41]
Secreted frizzled related protein 1	sFRP1	Secreted factor	[52]
Fibroblast growth factor 21	FGF21	Secreted factor	[58,59]
Sclerostin	SOST	Secreted factor	[64,140]
Dipeptidyl-peptidase-4 inhibitor	DPP4	Enzyme	[25]
Receptor activator of nuclear factor kappa-B ligand	RANKL	Secreted factor	[39,50]
Glucocorticoids	GC	Hormone	[141]
Glucose	Glu	Metabolite	[99–101]
Saturated fatty acids	FA	Metabolite	[94,95]
Reactive oxygen species	ROS	Metabolite	[142]

development of adipose tissue and enhanced bone mineral density (BMD) [36]. Also, recent analysis of a PPAR γ S112 mutation in mice, that prevented MAPK phosphorylation and inhibition of PPAR γ transcriptional activity, was associated with reduced trabecular bone, reduced bone formation, increased MAT and BMSC preferentially differentiated to adipocytes. Moreover, protein levels of total and phosphorylated RUNX2 declined [38].

The role of PPAR γ activation in age-related increase of MAT and decreased osteoblastogenesis has been shown in several studies. PPAR γ and CCAAT/enhancer-binding protein alpha (C/EBP α) were found to be increased in the BM of aged mice [39]. An increase in age-associated production of endogenous ligands of PPAR- γ 2 could exert the observed phenotype that enhances bone marrow adipogenesis at the expense of osteoblastogenesis e.g. dietary lipids, dyslipidemia, hyperlipidemia, use of medications like lipid lowering agents, glucocorticoids and thiazolidinediones [40].

3.4. CCAAT-enhancer binding proteins (C/EBP) family

Additional transcription factors involved in BMSC function and adipocyte differentiation are members of the C/EBP family: C/EBP α , C/EBP β , C/EBP γ and C/EBP δ . In BMSC, the function and activation of individual transcription factors exhibited a different pattern [41]. Moreover, it has been shown that an isoform of C/EBP β , liver-enriched inhibitory protein (LIP), which lacks transcriptional binding domain, induces activation of Runx2 and promotes osteoblast differentiation of BMSC [42]. C/EBPs crosstalk with PPAR γ and regulate each other via a feedback loop [43]. C/EBP β -deficient mice displayed reduced bone mineral density with decreased trabecular number [44,45]. These findings corroborate an important role of C/EBPs in the early stage of MSC differentiation and their commitment [46].

3.5. Forkhead box P1 (FOXP1)

In BMSC, FOXP1 expression levels decreased with age in an inverse manner with those of the senescence marker *p16INK4A*. Conditional depletion of *Foxp1* in BMSC leads to premature aging phenotype including increased bone marrow adiposity, decreased bone mass, and impaired BMSC self-renewal capacity in mice [47]. On the contrary, overexpression of FOXP1 augmented the replication capacity of BMSC irrespective of their age. FOXP1 influenced adipose cell-fate through interactions with the C/EBP β / δ key modulators of adipogenesis and directly repressed transcription of *p16INK4A* [47] [47].

(B) Age-related changes in the extrinsic factors in the BMSC micro-environment

The role of age-related changes of bone micro-environment in influencing BMSC biology has been demonstrated in transplantation experiments where BMSC of young donors favored adipogenesis and not osteoblastogenesis when transplanted *in vivo* in old mice [48]. Several factors present within the bone microenvironment are subject to age-

associated changes and thus, may affect BMSC differentiation capacity [49]. Examples of these factors are discussed here and summarized in Table 1.

3.6. Receptor activator of nuclear factor kappa-B ligand (RANKL)

RANKL present within the bone microenvironment has recently been demonstrated to be secreted by MAT [39,50]. Age-related changes in marrow adiposity are associated with increased RANKL expression. Takeshita et al. (2014) reported increased expression of RANKL by lineage committed BMSC in bone marrow of aged mice, leading to enhanced osteoclastogenesis [39].

3.7. Secreted frizzled-related protein 1 (sFRP)

We have previously identified sFRP1 as a secreted protein from adipocyte committed BMSC [51]. sFRP1 inhibits osteoblastogenesis and promotes adipogenesis of BMSC by blocking the Wnt signaling [52]. Similar effects of sFRP1 have been reported in preadipocytes and primary adipose tissue-derived cells [53,54]. The expression of sFRP1 mRNA levels was significantly increased in the biopsies from old as compared to young women [55]. With age, the increase in intrinsic stiffness of human trabecular meshwork cells is associated with increased sFRP1 expression [56].

3.8. Fibroblast growth factor 21 (FGF21)

FGF21 has been identified as a circulating hepatokine with effects on glucose and lipid metabolism and is secreted from adipose tissue and skeletal muscle [57]. FGF21 exerts a positive effect on adipogenesis via activation of PPAR γ in BMSC and adipose tissue progenitors. FGF21 deficient mice exhibit high bone mass and decreased fat formation. Reciprocally, mice overexpressing FGF21 exhibit reduced bone mass [58,59]. In older men, high serum levels of FGF21 are associated with low bone mass [60]. FGF21 can induce Insulin-like growth factor-binding protein 1 (IGFBP1), to activate Integrin beta 1 receptor and to stimulate osteoclast differentiation and bone resorption. IGFBP1 blockade is a potential strategy to prevent FGF21-induced bone loss [61].

3.9. Sclerostin (SOST)

SOST is a secreted protein of osteocytes and Wnt signaling inhibitor. It has been reported that serum levels of SOST increases in elderly people and is positively associated with increased MAT [62]. It is plausible that SOST inhibits bone formation and increases MAT through regulating differentiation of BMSC via inhibiting Wnt signaling [63,64].

3.10. Dipeptidyl-peptidase-4 (DPP4)

DPP4 is an exopeptidase shed from the plasma membrane, and its membrane-bound form is known as CD26. It is a ubiquitously expressed glycoprotein of 110kDa on the surface of a variety of cells [65]. DPP4 selectively cleaves the N-terminal dipeptides from a variety of substrates e.g. incretin hormones that stimulate a decrease in blood glucose levels. Soluble DPP4 was found to originate primarily from the bone marrow [66]. Recently, Ambrosi et al. showed that MAT produced DPP4, inhibiting bone fracture healing, suggesting a potential mechanism for the impairment of BMSC differentiation and bone regeneration [25]. DPP4 has been found to be selectively expressed on the surface of senescent but not proliferating human fibroblasts, its expression is increased in peripheral blood cells from elderly individuals and it can promote the senescence program [67].

3.11. Delta-like 1 (Dlk1)

Dlk1 (also known as fetal antigen 1 (FA1), or pre-adipocyte factor 1 (Pref-1)) is a factor secreted by committed BMSC progenitor cells in the bone microenvironment [68]. It is a member of the epidermal growth factor (EGF)-like protein family that includes proteins characterized by the presence of EGF-like motifs [69]. These proteins are involved in cell fate decision and cell differentiation processes in a variety of tissues.

Our group intensively examined the role of Dlk1/FA1 in lineage commitment and differentiation of hBMSC. Overexpressing Dlk1/FA1 in hBMSC resulted in inhibition of differentiation into mature osteoblasts and adipocytes and thus, maintenance of the undifferentiated hBMSC population [68]. The effect of Dlk1/FA1 on osteoblastic differentiation is mediated through a pathway downstream of Cbfa1/Runx2 since expression of Cbfa1/Runx2 was not affected and mature osteoblastic markers (alkaline phosphatase (ALP), collagen type I (Col1) and osteocalcin (OC)) were inhibited by over-expression of Dlk1/FA1. Similarly, Dlk1/FA1 overexpression in hBMSC, inhibited adipocyte differentiation by acting downstream on the early adipogenic commitment marker C/EBP β . Osteoblast-specific-Dlk1 over-expressing mice (Col1-Dlk1) [70] exhibited reduced total fat mass and bone mass, reduced bone formation rate, osteoblast surfaces and increased osteoclast surfaces. Interestingly, estrogen (E) deficiency which is the principal factor mediating post-menopausal bone loss, is associated with increased serum levels of Dlk1. Dlk1-deficient mice were significantly protected from OVX-induced bone loss. [71]. Thus, our data suggest that Dlk1/FA1 may mediate some of the E-deficiency-related bone loss.

3.12. Legumain (Lgmn)

We have recently identified legumain (Lgmn) as a novel regulator of BMSC differentiation [72]. Lgmn is a secreted cysteine protease involved in regulation of diverse physiological and pathological processes by remodeling tissue-specific targets (e.g. extracellular matrix (ECM) components, enzymes, receptors). We showed that Lgmn enhances adipocyte differentiation of hBMSC through degradation of the extracellular protein fibronectin which is an inhibitor of adipogenesis [73–75]. In addition, levels of Lgmn in hBMSC cultured from osteoporotic patients, are increased compared to young donors, and in bone biopsies high levels of Lgmn were associated with increased MAT and decreased trabecular bone mass [72].

(C) Age-related changes in systemic hormones

Aging is associated with significant changes in the endocrine system that exerts significant changes on BMSC biology. The role of some of the individual hormones will be presented here.

3.13. Glucocorticoids (GC)

GC are known to inhibit bone formation and high levels of GC in human (Cushing syndrome) are associated with increased risk of fractures and increased MAT formation. GC stimulates the synthesis of collagenase III, which is an enzyme involved in bone matrix degradation, inhibits the anabolic effect of IGF hormones and induces significant changes in neuropeptide Y that may contribute to osteoporosis and increased MAT phenotype [76]. Life-course time-point analysis has shown that circulating GC follow an age-related trajectory, which can be affected by both the external environment and internal physiological events, which varies between gender and individuals [77].

3.14. Growth hormone (GH) and insulin-like growth factors

GH is an important hormone regulating bone growth and energy metabolism [78]. GH levels decrease with age and are associated with bone loss. It has been shown that GH is a negative regulator of bone

adiposity. GH increases osteoblast differentiation while suppressing bone marrow lipid accumulation in GH deficient animal model [79].

Insulin-like growth factor 1 (IGF1) is considered one of the most important mediators of bone growth. Systemic IGF1 is synthesized primarily in the liver, where its synthesis is GH dependent. IGF1 plasma half-life and the interaction of IGF1 with its receptor (IGF1R) is regulated either positively or negatively by a family of six high-affinity IGF binding proteins (IGFBPs; IGFBP1 to IGFBP6). Tissue responsiveness to IGF1 is altered with aging in many tissues [80]. In bone, IGF1 responsiveness decreased with aging [81,82]. The mitogenic response of osteoblasts derived from patients of different ages require higher concentration of IGF1 with increasing age [82]. Increased serum IGF1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue IGF1 gene expression [83]. These studies suggest that IGF1 may play a protective role in the young skeleton and its age-related decline leads to bone fragility and an increased fracture risk.

3.15. Thyroid hormones (TH)

TH exert a negative effect on MAT. Mice deficient in TH exhibit growth retardation, lower BMD and increased bone adiposity [84,85]. Circulating free TH levels usually decrease with aging, leading to hypothyroidism which is among the most frequent chronic diseases in the elderly [86]. However, the incidence of mild hyperthyroidism also increases with increasing age, especially in > 70 year old populations with historical or current iodine deficiency [87]. Hyperthyroidism was shown to have a negative effect on bone metabolism via accelerating bone turnover and decrease of BMD through increased osteoclast activation and dysregulation of calcium metabolism [88,89]. However, it is not known whether higher TH levels causes increase MAT formation.

(D) Age-related changes in metabolism and metabolic stimuli

Obesity increases with aging and is associated with low grade inflammation, lipotoxicity and impaired glucose metabolism. We have recently demonstrated a negative impact of obesity-induced diet on BMSC with increased MAT, decreased bone formation, skeletal stem cell exhaustion [90]. Another animal study reported impairment of mitochondrial function and apoptosis of BMSC in obese mice [91]. Patients with type 1 and type 2 diabetes exhibit increased MAT formation and a risk for bone fractures [92]. Thus, defective systemic metabolism affects differentiation capacity and function of BMSC. Several factors have been studied in relation to BMSC biology and bone fragility. Some of them are discussed here below and depicted in Fig. 1 and Table 1.

3.16. Fatty acids (FA)

An *in vitro* study showed that BMSC incubated with sera obtained from overweight persons enhances adipocyte differentiation and diminishes osteoblast differentiation [93], suggesting that secreted factors/nutrients present in circulation can affect the differentiation of BMSC. Saturated FA affect cell survival and proliferation of hBMSC [94,95]. Also, saturated FA peroxidation produce reactive oxygen species (ROS) and activate signaling pathways leading to cellular senescence and apoptosis [95–97]. Additional suggestive evidence for the role of FA metabolism in regulating BMSC functions is the presence of lower FA saturation index as determined by high resolution magic angle spinning (HRMAS) ¹H NMR spectroscopy, in the MAT of subjects with lower BMD [98].

3.17. Glucose

There is an age-related increase in glucose levels that may have effects on BMSC biology. *In vitro* studies have shown that high glucose levels induce increased adipogenesis and decreased proliferation

capacity of BMSC in mice and human [99–101]. One proposed mechanism is changes in the levels of transforming growth factor- β (TGF- β) signaling leading to changes of lineage allocation of BMSC from osteoblast to adipocyte differentiation in murine BMSC [102]. High glucose levels induce cell senescence by activating autophagy in hBMSC [103]. Chronic exposure to high levels of glucose and insulin stimulate BMSC adipogenic differentiation [104].

3.18. Glucagon-like-peptide-1 (GLP-1)

Activation of BMSC-expressing GLP-1 receptor by exendin-4, a GLP-1 agonist, promote the osteogenic differentiation and inhibited adipocytic differentiation through regulating PKA/ β -catenin and PKA/PI3K/AKT/GSK3 β signaling [105]. Exendin-4 also improved BMSC proliferation and cell motility [106]. Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics significantly increased trabecular bone mass, in OVX mice [107]. The role of GLP1 in regulating BMSC biology remains to be determined.

4. Possible approaches for pharmacological/therapeutic targeting of the BMA

The clinical use of BMSC in clinical regenerative medicine protocols to treat bone fragility and impaired fracture healing in osteoporotic elderly patients, has been hampered by several challenges [108]. Interventions to *in vivo* targeting of BMSC may prove beneficial to enhance bone formation and skeletal repair. Several possible interventions are described below.

4.1. Estrogen (E)

Evidence that BMSC is targeted by E is derived from clinical studies showing that MAT increases during menopause and is inversely related to bone mass due to E deficiency [13]. Also, MAT mass is greater in postmenopausal women compared to premenopausal women and men [109]. E has been shown to affect adipocyte development and function at multiple levels (reviewed in [110]) and to directly inhibit adipocyte differentiation [111,112]. Also, E exerts an inhibitory effect on adipose tissue formation through regulation of energy expenditure and food consumption [113]. One-year treatment of postmenopausal osteoporotic women with transdermal E increased bone mass and decreased the MAT mass and BMA number as compared to placebo-treated controls [114]. Also, treatment of 6 postmenopausal women with oral 17 β -estradiol (2 mg/day) resulted in a reduction of the vertebral MAT fraction [109].

4.2. Parathyroid hormone (PTH)

Several studies have demonstrated that PTH treatment targets BMSC lineage allocation and differentiation fate [50]. Intermittent treatment with PTH has anabolic effect on bone formation, enhances Wnt signaling and increases osteoblast differentiation [115]. Treatment of postmenopausal women, with fragility fractures and low BMD, with daily injections of PTH for 18 to 24 months, resulted in decreased MAT without change in adipocyte number, as assessed in bone biopsies [116]. In another clinical study, PTH treatment decreased MAT in postmenopausal women following 12-month therapy, as judged by T1 weighted MRI scanning [117]. A recent paper by Fan et al. reported that PTH inhibits expansion of pro-adipogenic progenitors and that in PTHr1 KO mice there exists an impaired bone formation and enhanced bone adiposity [50].

4.3. Strontium Ranelate (SrRN)

Strontium Ranelate (SrRN) has been used for treatment of osteoporosis [118]. SrRN increases bone formation and decreases bone

resorption through multiple mechanisms, such as increasing osteoblast proliferation, differentiation, and survival, as well as decreasing osteoclast differentiation and function (reviewed in [118]). In addition, SrRN exerts a dose-dependent inhibitory effect on adipocyte differentiation of BMSC *in vitro* and *in vivo* [119–121], and prevents lipotoxicity within the bone marrow milieu [119]. SrRN treatment increases bone mass and reduces MAT in SAMP6 accelerated senescent mice through stimulation of Wnt and NFATc/Maf pathways, and consequent inhibition of adipogenesis due to repressed PPAR γ expression [121].

4.4. Rejuvenation factors

Several systemic factors with potential rejuvenating effects have been identified from studies of heterochronic parabiosis. Recent works on the subject, reviewed in [122], have shed a perspective on the intricacies pertaining these factors.

One of the growth differentiation factors (GDF) which is subfamily of proteins belonging to the TGF β superfamily, GDF11 has been reported as a potent regulator of bone metabolism [123]. It does so by inhibiting the activity of PPAR γ , promoting osteoblastogenesis and inhibiting adipogenesis from BMSC. Serum levels of GDF11 are decreased in patients with osteoporosis compared to normal age-matched donors [123]. Other studies reported contradictory effects as injection of GDF11 into mice inhibited bone formation and accelerated age-related bone loss [124]. Thus, whether GDF11 can be employed to target lineage fate of BMSC awaits further studies.

4.5. Phytochemicals and natural compounds

Several bioactive molecules potentially inhibiting adipogenic differentiation and enhancing osteogenic differentiation have been identified in animal and cell culture models [125]. For example, resveratrol, a phytoalexin known to be a caloric restriction mimetic, is long known to inhibit adipogenic differentiation and increase osteogenesis of BMSC [126,127]. Resveratrol has many other beneficial anti-aging functions e.g. regulating lipolysis, mitochondrial biogenesis and thermogenesis. The effects are mediated in part by activation of SIRT1, a member of the sirtuin family of histone deacetylases [126]. Preclinical studies in aged OVX female rats treated with vitamin D combined with genistein, quercetin, and resveratrol exhibited increased BMD, reduced body weight gain and a significant decrease in BMA [128]. Puerarin, a phytoestrogen extracted from *Pueraria lobata* (Willd.) Ohwi, a plant used in Chinese traditional medicine, is known to have anti-osteoporotic effects. Puerarin and zinc promoted the serological level of osteocalcin, BMSC proliferation, and the expression of alkaline phosphatase, and decreased MAT mass [129].

Asiatic acid (AA), a triterpenoid found in *Centella asiatica*, inhibited the adipogenic induction of lipid accumulation, the activity of glycerol-3-phosphate dehydrogenase, and expression of BMSC through inhibition of PPAR γ through C/EBP β -independent mechanisms [130]. Isosporalen (ISO) is the main active ingredient extracted from the seeds of *Psoralea corylifolia*, a Chinese herb used in the treatment of fractures, and bone and joint diseases. ISO attenuated bone marrow adipogenesis, caused increased RUNX2 and decreased PPAR γ levels, resulting in a BMSC shift in lineage differentiation from adipocytes to osteoblasts, involving the mTORC1 signaling pathway [131]. Sodium butyrate, a known histone deacetylase (HDAC) inhibitor, decreases proliferation potential and multilineage differentiation capability of BMSC [132]. Also, genistein, epigallocatechin and various oxysterols have been found to inhibit PPAR γ expression and adipogenic differentiation of BMSC [125,133].

4.6. Probiotics and the role of age-related changes in microbiota

Many reports have revealed the importance of the gut microbiota on

healthy aging [134] and human longevity, as reviewed in [135]. Although the core communities, belonging to the Ruminococcaceae, Lachnospiraceae and Bacteroidaceae families, decrease with age, a longevity adaptation in some individuals promote the enrichment of health-associated taxa, such as Akkermansia and Bifidobacterium, known to activate immunomodulation, protect against inflammation, and promote a healthy metabolic homeostasis, that might support extreme aging and longevity [136]. A summary of gut microbiota composition and its role in bone loss during aging and osteoporosis has been published [137].

The gut microbiota is known to induce IGF1 which promotes bone formation and skeletal growth [138]. In another study, the microbiota contributed to increase adipogenesis, inhibit osteogenesis and enhance the immunomodulatory capacity of BMSC. Probiotic and prebiotic treatments were able to increase bone mass and BMD, indicating that intestinal microbiota may impact on BMSC biological functions and differentiation [139].

5. Conclusions and future perspectives

The mechanisms of age-related changes in BMSC are currently an important topic of bone biology studies as they may uncover novel approaches for treating age-related bone fragility and osteoporosis. While the *in vitro* mechanistic studies have identified several principal age-related pathways, their targeting *in vivo* to determine relevance and efficacy need to be performed. The development of non-invasive imaging technologies that can monitor MAT formation and bone mass changes in humans will allow translation of results obtained in pre-clinical animal models to the clinic. Targeted elimination of bone-specific senescent cell subsets is a promising therapeutic approach to prevent or delay osteoporosis. We expect that in the coming decade, we will witness the development of several novel approaches to target age-related changes in BMSC to treat age-related bone fragility and risk.

Disclosures

The authors do not have any conflicts of interests to disclose.

Acknowledgements

The work presented here was supported by funds from the Danish Diabetes Academy, the Novo Nordisk Foundation (NNF18OC0034186 and NNF17OC0029290) and the Lundbeck Foundation (R266-2017-4250).

References

- [1] N.A. Sims, T.J. Martin, Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit, *Bonekey Rep.* 3 (2014) 481.
- [2] J. Justesen, K. Stenderup, E.N. Ebbesen, L. Mosekilde, T. Steiniche, M. Kassem, Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis, *Biogerontology* 2 (3) (2001) 165–171.
- [3] Z. Li, J. Hardij, D.P. Bagchi, E.L. Scheller, O.A. MacDougald, Development, regulation, metabolism and function of bone marrow adipose tissues, *Bone* 110 (2018) 134–140.
- [4] M. Kassem, P. Bianco, Skeletal stem cells in space and time, *Cell* 160 (1–2) (2015) 17–19.
- [5] M. Kassem, P.J. Marie, Senescence-associated intrinsic mechanisms of osteoblast dysfunctions, *Aging Cell* 10 (2) (2011) 191–197.
- [6] P.J. Marie, M. Kassem, Extrinsic mechanisms involved in age-related defective bone formation, *J. Clin. Endocrinol. Metab.* 96 (3) (2011) 600–609.
- [7] P. Hardouin, V. Pansini, B. Cortet, Bone marrow fat, *Joint Bone Spine* 81 (4) (2014) 313–319.
- [8] K.J. Suchacki, W.P. Cawthorn, C.J. Rosen, Bone marrow adipose tissue: formation, function and regulation, *Curr. Opin. Pharmacol.* 28 (2016) 50–56.
- [9] M. Tavassoli, Fatty involution of marrow and the role of adipose tissue in hemopoiesis, in: M. Tavassoli (Ed.), *Handbook of the Hemopoietic Microenvironment. Contemporary Biomedicine*, 9 Humana Press, 1989, pp. 157–187.
- [10] A. Piney, Anatomy of the bone marrow with special reference to the distribution of red marrow, *Br. Med. J.* 2 (1922) 792–795.

- [11] M. Askanazi, F. Henke, O. Lubrasch (Eds.), *Handbuch der Speziellen Pathologischen Anatomie und Histologie*, 1,2 Springer, Berlin, 1927, p. 775.
- [12] D.K. Yeung, J.F. Griffith, G.E. Antonio, F.K. Lee, J. Woo, P.C. Leung, Osteoporosis is associated with increased marrow fat content and decreased marrow fat unsaturation: a proton MR spectroscopy study, *J. Magn. Reson. Imaging* 22 (2) (2005) 279–285.
- [13] J.F. Griffith, D.K. Yeung, H.T. Ma, J.C. Leung, T.C. Kwok, P.C. Leung, Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects, *J. Magn. Reson. Imaging* 36 (1) (2012) 225–230.
- [14] B.G. Childs, M. Gluscevic, D.J. Baker, R.M. Laberge, D. Marquess, J. Dananberg, et al., Senescent cells: an emerging target for diseases of ageing, *Nat. Rev. Drug Discov.* 16 (10) (2017) 718–735.
- [15] J.N. Farr, D.G. Fraser, H. Wang, K. Jaehn, M.B. Ogronnik, M.M. Weivoda, et al., Identification of senescent cells in the bone microenvironment, *J. Bone Miner. Res.* 31 (11) (2016) 1920–1929.
- [16] K. Stenderup, C. Rosada, J. Justesen, T. Al-Soubky, F. gnaes-Hansen, M. Kassem, Aged human bone marrow stromal cells maintaining bone forming capacity in vivo evaluated using an improved method of visualization, *Biogerontology* 5 (2) (2004) 107–118.
- [17] S. Zhou, J.S. Greenberger, M.W. Epperly, J.P. Goff, C. Adler, M.S. Leboff, et al., Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts, *Aging Cell* 7 (3) (2008) 335–343.
- [18] R.J. Pignolo, R.K. Suda, E.A. McMillan, J. Shen, S.H. Lee, Y. Choi, et al., Defects in telomere maintenance molecules impair osteoblast differentiation and promote osteoporosis, *Aging Cell* 7 (1) (2008) 23–31.
- [19] M. Almeida, C.A. O'Brien, Basic biology of skeletal aging: role of stress response pathways, *J. Gerontol. A Biol. Sci. Med. Sci.* 68 (10) (2013) 1197–1208.
- [20] L. Liao, X. Su, X. Yang, C. Hu, B. Li, Y. Lv, et al., TNF-alpha inhibits FoxO1 by upregulating miR-705 to aggravate oxidative damage in bone marrow-derived mesenchymal stem cells during osteoporosis, *Stem Cells* 34 (4) (2016) 1054–1067.
- [21] H.N. Kim, J. Chang, L. Shao, L. Han, S. Iyer, S.C. Manolagas, et al., DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age, *Aging Cell* 16 (4) (2017) 693–703.
- [22] R.J. Bergman, D. Gazit, A.J. Kahn, H. Gruber, S. McDougall, T.J. Hahn, Age-related changes in osteogenic stem cells in mice, *J. Bone Miner. Res.* 11 (5) (1996) 568–577.
- [23] D. Egrise, D. Martin, A. Vienne, P. Neve, A. Schoutens, The number of fibroblastic colonies formed from bone marrow is decreased and the in vitro proliferation rate of trabecular bone cells increased in aged rats, *Bone* 13 (5) (1992) 355–361.
- [24] I. Bellantuono, A. Aldahmash, M. Kassem, Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss, *Biochim. Biophys. Acta* 1792 (4) (2009) 364–370.
- [25] T.H. Ambrosi, A. Scialdone, A. Graja, S. Gohlke, A.M. Jank, C. Bocian, et al., Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration, *Cell Stem Cell* 20 (6) (2017) 771–784 (e6).
- [26] H. Kawamura, R. Nakatsuka, Y. Matsuoka, K. Sumide, T. Fujioka, H. Asano, et al., TGF-beta signaling accelerates senescence of human bone-derived CD271 and SSEA-4 double-positive mesenchymal stromal cells, *Stem Cell Reports* 10 (3) (2018) 920–932.
- [27] O. Kajkenova, B. Lecka-Czernik, I. Gubrij, S.P. Hauser, K. Takahashi, A.M. Parfitt, et al., Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia, *J. Bone Miner. Res.* 12 (11) (1997) 1772–1779.
- [28] E.J. Moerman, K. Teng, D.A. Lipschitz, B. Lecka-Czernik, Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways, *Aging Cell* 3 (6) (2004) 379–389.
- [29] W.S. Khan, A.B. Adesida, S.R. Tew, J.G. Andrew, T.E. Hardingham, The epitope characterisation and the osteogenic differentiation potential of human fat pad-derived stem cells is maintained with ageing in later life, *Injury* 40 (2) (2009) 150–157.
- [30] H. Cheng, L. Qiu, J. Ma, H. Zhang, M. Cheng, W. Li, et al., Replicative senescence of human bone marrow and umbilical cord derived mesenchymal stem cells and their differentiation to adipocytes and osteoblasts, *Mol. Biol. Rep.* 38 (8) (2011) 5161–5168.
- [31] M.C. Mitterberger, S. Lechner, M. Mattesich, W. Zwierschke, Adipogenic differentiation is impaired in replicative senescent human subcutaneous adipose-derived stromal/progenitor cells, *J. Gerontol. A Biol. Sci. Med. Sci.* 69 (1) (2014) 13–24.
- [32] K. Stenderup, J. Justesen, C. Clausen, M. Kassem, Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells, *Bone* 33 (6) (2003) 919–926.
- [33] B.M. Abdallah, A. Jafari, W. Zaher, W. Qiu, M. Kassem, Skeletal (stromal) stem cells: an update on intracellular signaling pathways controlling osteoblast differentiation, *Bone* 70 (2015) 28–36.
- [34] I. Takada, A.P. Kouzmenko, S. Kato, Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis, *Nat. Rev. Rheumatol.* 5 (8) (2009) 442–447.
- [35] D.Y. Zhang, H.J. Wang, Y.Z. Tan, Wnt/beta-catenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway, *PLoS One* 6 (6) (2011) e21397.
- [36] T. Akune, S. Ohba, S. Kamekura, M. Yamaguchi, U.I. Chung, N. Kubota, et al., PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors, *J. Clin. Invest.* 113 (6) (2004) 846–855.
- [37] J.M. Gimble, C.E. Robinson, X. Wu, K.A. Kelly, B.R. Rodriguez, S.A. Kliewer, et al., Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells, *Mol. Pharmacol.* 50 (5) (1996) 1087–1094.
- [38] C. Ge, G. Zhao, B. Li, Y. Li, W.P. Cawthorn, O.A. MacDougald, et al., Genetic inhibition of PPARgamma S112 phosphorylation reduces bone formation and stimulates marrow adipogenesis, *Bone* 107 (2018) 1–9.
- [39] S. Takeshita, T. Fumoto, Y. Naoe, K. Ikeda, Age-related marrow adipogenesis is linked to increased expression of RANKL, *J. Biol. Chem.* 289 (24) (2014) 16699–16710.
- [40] H. Sadie-Van Gijsen, F.S. Hough, W.F. Ferris, Determinants of bone marrow adiposity: the modulation of peroxisome proliferator-activated receptor-gamma2 activity as a central mechanism, *Bone* 56 (2) (2013) 255–265.
- [41] S.W. Qian, X. Li, Y.Y. Zhang, H.Y. Huang, Y. Liu, X. Sun, et al., Characterization of adipocyte differentiation from human mesenchymal stem cells in bone marrow, *BMC Dev. Biol.* 10 (2010) 47.
- [42] K. Hata, R. Nishimura, M. Ueda, F. Ikeda, T. Matsubara, F. Ichida, et al., A CCAAT/enhancer binding protein beta isoform, liver-enriched inhibitory protein, regulates commitment of osteoblasts and adipocytes, *Mol. Cell. Biol.* 25 (5) (2005) 1971–1979.
- [43] E.D. Rosen, Molecular mechanisms of adipocyte differentiation, *Ann. Endocrinol. (Paris)* 63 (2 Pt 1) (2002) 79–82.
- [44] J. Staiger, M.J. Lueben, D. Berrigan, R. Malik, S.N. Perkins, S.D. Hursting, et al., C/EBPbeta regulates body composition, energy balance-related hormones and tumor growth, *Carcinogenesis* 30 (5) (2009) 832–840.
- [45] S. Zanotti, L. Stadmeier, A. Smerdel-Ramoya, D. Durant, E. Canalis, Misexpression of CCAAT/enhancer binding protein beta causes osteopenia, *J. Endocrinol.* 201 (2) (2009) 263–274.
- [46] H. Tominaga, S. Maeda, M. Hayashi, S. Takeda, S. Akira, S. Komiyama, et al., CCAAT/enhancer-binding protein beta promotes osteoblast differentiation by enhancing Runx2 activity with ATF4, *Mol. Biol. Cell* 19 (12) (2008) 5373–5386.
- [47] H. Li, P. Liu, S. Xu, Y. Li, J.D. Dekker, B. Li, et al., FOXO1 controls mesenchymal stem cell commitment and senescence during skeletal aging, *J. Clin. Invest.* 127 (4) (2017) 1241–1253.
- [48] L. Singh, T.A. Brennan, E. Russell, J.H. Kim, Q. Chen, F. Brad Johnson, et al., Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage, *Bone* 85 (2016) 29–36.
- [49] B.M. Abdallah, M. Kassem, New factors controlling the balance between osteoblastogenesis and adipogenesis, *Bone* 50 (2) (2012) 540–545.
- [50] Y. Fan, J.I. Hanai, P.T. Le, R. Bi, D. Maridas, V. DeMambro, et al., Parathyroid hormone directs bone marrow mesenchymal cell fate, *Cell Metab.* 25 (3) (2017) 661–672.
- [51] S. Post, B.M. Abdallah, J.F. Bentzon, M. Kassem, Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells, *Bone* 43 (1) (2008) 32–39.
- [52] H. Taipaleenmaki, B.M. Abdallah, A. Aldahmash, A.M. Saamanen, M. Kassem, Wnt signalling mediates the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations, *Exp. Cell Res.* 317 (6) (2011) 745–756.
- [53] C.N. Bennett, S.E. Ross, K.A. Longo, L. Bajnok, N. Hemati, K.W. Johnson, et al., Regulation of Wnt signaling during adipogenesis, *J. Biol. Chem.* 277 (34) (2002) 30998–31004.
- [54] C. Lagathu, C. Christodoulides, C.Y. Tan, S. Virtue, M. Laudes, M. Campbell, et al., Secreted frizzled-related protein 1 regulates adipose tissue expansion and is dysregulated in severe obesity, *Int. J. Obes.* 34 (12) (2010) 1695–1705.
- [55] M.M. Roforth, K. Fujita, U.I. McGregor, S. Kirmani, L.K. McCready, J.M. Peterson, et al., Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans, *Bone* 59 (2014) 1–6.
- [56] J.T. Morgan, V.K. Raghunathan, Y.R. Chang, C.J. Murphy, P. Russell, The intrinsic stiffness of human trabecular meshwork cells increases with senescence, *Oncotarget* 6 (17) (2015) 15362–15374.
- [57] N. Itoh, FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases, *Front. Endocrinol. (Lausanne)* 5 (2014) 107.
- [58] P.A. Dutchak, T. Katafuchi, A.L. Bookout, J.H. Choi, R.T. Yu, D.J. Mangelsdorf, et al., Fibroblast growth factor-21 regulates PPARgamma activity and the anti-diabetic actions of thiazolidinediones, *Cell* 148 (3) (2012) 556–567.
- [59] W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, A.L. Bookout, et al., Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma, *Proc. Natl. Acad. Sci. U. S. A.* 109 (8) (2012) 3143–3148.
- [60] L.J. Hanks, O.M. Gutierrez, M.M. Bamman, A. Ashraf, K.L. McCormick, K. Casazza, Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals, *J. Clin. Transl. Endocrinol.* 2 (2) (2015) 77–82.
- [61] X. Wang, W. Wei, J.Y. Krzeszinski, Y. Wang, Y. Wan, A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption, *Cell Metab.* 22 (5) (2015) 811–824.
- [62] Y.H. Ma, A.V. Schwartz, S. Sigurdsson, T.F. Hue, T.F. Lang, T.B. Harris, et al., Circulating sclerostin associated with vertebral bone marrow fat in older men but not women, *J. Clin. Endocrinol. Metab.* 99 (12) (2014) E2584–E2590.
- [63] R.L. van Bezooijen, B.A. Roelen, A. Visser, L. van der Wee-Pals, E. de Wilt, M. Karperien, et al., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist, *J. Exp. Med.* 199 (6) (2004) 805–814.
- [64] H. Fairfield, C. Falank, E. Harris, V. Demambro, M. McDonald, J.A. Pettitt, et al., The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis, *J. Cell. Physiol.* 233 (2) (2018) 1156–1167.
- [65] D. Rohrborn, N. Wronkowitz, J. Eckel, DPP4 in Diabetes, *Front. Immunol.* 6 (2015) 386.

- [66] Z. Wang, C. Grigo, J. Steinbeck, S. von Horsten, K. Amann, C. Daniel, Soluble DPP4 originates in part from bone marrow cells and not from the kidney, *Peptides* 57 (2014) 109–117.
- [67] K.M. Kim, J.H. Noh, M. Bodogai, J.L. Martindale, X. Yang, F.E. Indig, et al., Identification of senescent cell surface targetable protein DPP4, *Genes Dev.* 31 (15) (2017) 1529–1534.
- [68] B.M. Abdallah, C.H. Jensen, G. Gutierrez, R.G. Leslie, T.G. Jensen, M. Kassem, Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1, *J. Bone Miner. Res.* 19 (5) (2004) 841–852.
- [69] C.M. Smas, H.S. Sul, Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation, *Cell* 73 (4) (1993) 725–734.
- [70] B.M. Abdallah, N. Ditzel, A. Mahmood, A. Isa, G.A. Traustadottir, A.F. Schilling, et al., DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice, *J. Bone Miner. Res.* 26 (7) (2011) 1457–1471.
- [71] B.M. Abdallah, A.C. Bay-Jensen, B. Srinivasan, N.C. Tabassi, P. Garnerio, J.M. Delaisse, et al., Estrogen inhibits Dlk1/FAI production: a potential mechanism for estrogen effects on bone turnover, *J. Bone Miner. Res.* 26 (10) (2011) 2548–2551.
- [72] A. Jafari, D. Qanie, T.L. Andersen, Y. Zhang, L. Chen, B. Postert, et al., Legumain regulates differentiation fate of human bone marrow stromal cells and is altered in postmenopausal osteoporosis, *Stem Cell Reports* 8 (2) (2017) 373–386.
- [73] B.M. Spiegelman, C.A. Ginty, Fibronectin modulation of cell shape and lipogenic gene expression in 3T3-adipocytes, *Cell* 35 (3 Pt 2) (1983) 657–666.
- [74] J.L. Rodriguez Fernandez, A. Ben-Ze'ev, Regulation of fibronectin, integrin and cytoskeleton expression in differentiating adipocytes: inhibition by extracellular matrix and polylysine, *Differentiation* 42 (2) (1989) 65–74.
- [75] J. Antras, F. Hilliou, G. Redziniak, J. Pairault, Decreased biosynthesis of actin and cellular fibronectin during adipose conversion of 3T3-F442A cells. Reorganization of the cytoarchitecture and extracellular matrix fibronectin, *Biology of the Cell/Under the Auspices of the European Cell Biology Organization* 66 (3) (1989) 247–254.
- [76] F.S. Wang, W.S. Lian, W.T. Weng, Y.C. Sun, H.J. Ke, Y.S. Chen, et al., Neuropeptide Y mediates glucocorticoid-induced osteoporosis and marrow adiposity in mice, *Osteoporos. Int.* 27 (9) (2016) 2777–2789.
- [77] E. Zambrano, L.A. Reyes-Castro, P.W. Nathanielsz, Aging, glucocorticoids and developmental programming, *Age (Dordr.)* 37 (3) (2015) 9774.
- [78] C. Ohlsson, B.A. Bengtsson, O.G. Isaksson, T.T. Andreassen, M.C. Sloopweg, Growth hormone and bone, *Endocr. Rev.* 19 (1) (1998) 55–79.
- [79] P.J. Menagh, R.T. Turner, D.B. Jump, C.P. Wong, M.B. Lowry, S. Yakar, et al., Growth hormone regulates the balance between bone formation and bone marrow adiposity, *J. Bone Miner. Res.* 25 (4) (2010) 757–768.
- [80] S. Perrini, L. Laviola, M.C. Carreira, A. Cignarelli, A. Natalicchio, F. Giorgino, The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis, *J. Endocrinol.* 205 (3) (2010) 201–210.
- [81] M. Kveiborg, A. Flyvbjerg, S.I. Rattan, M. Kassem, Changes in the insulin-like growth factor-system may contribute to in vitro age-related impaired osteoblast functions, *Exp. Gerontol.* 35 (8) (2000) 1061–1074.
- [82] J. Pfeilschifter, I. Diel, U. Pilz, K. Brunotte, A. Naumann, R. Ziegler, Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age, *J. Bone Miner. Res.* 8 (6) (1993) 707–717.
- [83] S. Elis, Y. Wu, H.W. Courtland, H. Sun, C.J. Rosen, M.L. Adamo, et al., Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression, *Aging Cell* 10 (3) (2011) 547–550.
- [84] J.M. Kindblom, E.F. Gevers, S.M. Skrtic, M.K. Lindberg, S. Gothe, J. Tornell, et al., Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors, *Bone* 36 (4) (2005) 607–616.
- [85] M.H. Sheng, X.D. Zhou, L.F. Bonewald, D.J. Baylink, K.H. Lau, Disruption of the insulin-like growth factor-1 gene in osteocytes impairs developmental bone growth in mice, *Bone* 52 (1) (2013) 133–144.
- [86] V. Calsolari, F. Niccolai, G. Pasqualetti, S. Tognini, S. Magno, T. Riccioni, et al., Hypothyroidism in the elderly: who should be treated and how? *J. Endocr. Soc.* 3 (1) (2019) 146–158.
- [87] G. Barbesino, Thyroid function changes in the elderly and their relationship to cardiovascular health: a mini-review, *Gerontology* (2018) 1–8.
- [88] D. Tuchendler, M. Bolanowski, The influence of thyroid dysfunction on bone metabolism, *Thyroid. Res.* 7 (1) (2014) 12.
- [89] P. Vestergaard, L. Mosekilde, Hyperthyroidism, bone mineral, and fracture risk—a meta-analysis, *Thyroid* 13 (6) (2003) 585–593.
- [90] M. Tencerova, F. Figeac, N. Ditzel, H. Taipaleenmaki, T.K. Nielsen, M. Kassem, High fat diet-induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice, *J. Bone Miner. Res.* 33 (6) (2018) 1154–1165.
- [91] G.P. de Oliveira, E. Cortez, G.J. Araujo, K.C. de Carvalho Sabino, F.A. Neves, A.F. Bernardo, et al., Impaired mitochondrial function and reduced viability in bone marrow cells of obese mice, *Cell Tissue Res.* 357 (1) (2014) 185–194.
- [92] B. Lecka-Czernik, C.J. Rosen, Skeletal integration of energy homeostasis: translational implications, *Bone* 82 (2016) 35–41.
- [93] G. Di Bernardo, G. Messina, S. Capasso, S. Del Gaudio, M. Cipollaro, G. Peluso, et al., Sera of overweight people promote in vitro adipocyte differentiation of bone marrow stromal cells, *Stem Cell Res Ther* 5 (1) (2014) 4.
- [94] A. Casado-Diaz, C. Ferreiro-Vera, F. Priego-Capote, G. Dorado, M.D. Luque-de-Castro, J.M. Quesada-Gomez, Effects of arachidonic acid on the concentration of hydroxyeicosatetraenoic acids in culture media of mesenchymal stromal cells differentiating into adipocytes or osteoblasts, *Genes Nutr.* 9 (1) (2014) 375.
- [95] N. Fillmore, A. Huqi, J.S. Jaswal, J. Mori, R. Paulin, A. Haromy, et al., Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survival, *PLoS One* 10 (3) (2015) e0120257.
- [96] A.W. Alund, K.E. Mercer, L.J. Suva, C.F. Pulliam, J.R. Chen, T.M. Badger, et al., Reactive oxygen species differentially regulate bone turnover in an age-specific manner in catalase transgenic female mice, *J. Pharmacol. Exp. Ther.* 358 (1) (2016) 50–60.
- [97] D.G. Tang, E. La, J. Kern, J.P. Kehrer, Fatty acid oxidation and signaling in apoptosis, *Biol. Chem.* 383 (3–4) (2002) 425–442.
- [98] X. Li, K. Shet, K. Xu, J.P. Rodriguez, A.M. Pino, J. Kurhanewicz, et al., Unsaturation level decreased in bone marrow fat of postmenopausal women with low bone density using high resolution magic angle spinning (HRMAS) ¹H NMR spectroscopy, *Bone* 105 (2017) 87–92.
- [99] C.C. Chuang, R.S. Yang, K.S. Tsai, F.M. Ho, S.H. Liu, Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling, *Endocrinology* 148 (9) (2007) 4267–4275.
- [100] P. Aguiari, S. Leo, B. Zavan, V. Vindigni, A. Rimessi, K. Bianchi, et al., High glucose induces adipogenic differentiation of muscle-derived stem cells, *Proc. Natl. Acad. Sci. U. S. A.* 105 (4) (2008) 1226–1231.
- [101] Y.M. Li, T. Schilling, P. Benisch, S. Zeck, J. Meissner-Weigl, D. Schneider, et al., Effects of high glucose on mesenchymal stem cell proliferation and differentiation, *Biochem. Biophys. Res. Commun.* 363 (1) (2007) 209–215.
- [102] J.J.Y. Kum, C.J. Howlett, Z.A. Khan, High glucose alters transforming growth factor-β signaling to switch from osteogenic to adipogenic differentiation in bone marrow cells, *Can. J. Diabetes* 41 (5) (2017) Suppl., S9.
- [103] T.C. Chang, M.F. Hsu, K.K. Wu, High glucose induces bone marrow-derived mesenchymal stem cell senescence by upregulating autophagy, *PLoS One* 10 (5) (2015) e0126537.
- [104] A.H. Chaves Neto, V.G. Balera Brito, T.L. de Barros, C. Amaral, D.H. Sumida, S.H. Penha Oliveira, Chronic high glucose and insulin stimulate bone-marrow stromal cells adipogenic differentiation in young spontaneously hypertensive rats, *J. Cell. Physiol.* 233 (9) (2018) 6853–6865.
- [105] J. Meng, X. Ma, N. Wang, M. Jia, L. Bi, Y. Wang, et al., Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin, *Stem Cell Reports* 6 (4) (2016) 633.
- [106] H. Zhou, D. Li, C. Shi, T. Xin, J. Yang, Y. Zhou, et al., Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro, *Sci. Rep.* 5 (2015) 12898.
- [107] M. Pereira, J. Jeyabalan, C.S. Jorgensen, M. Hopkinson, A. Al-Jazzar, J.P. Roux, et al., Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice, *Bone* 81 (2015) 459–467.
- [108] W.L. Grayson, B.A. Bunnell, E. Martin, T. Frazier, B.P. Hung, J.M. Gimble, Stromal cells and stem cells in clinical bone regeneration, *Nat. Rev. Endocrinol.* 11 (3) (2015) 140–150.
- [109] E.J. Limonard, A.G. Veldhuis-Vlug, L. van Dussen, J.H. Runge, M.W. Tanck, E. Endert, et al., Short-term effect of estrogen on human bone marrow fat, *J. Bone Miner. Res.* 30 (11) (2015) 2058–2066.
- [110] P.S. Cooke, A. Naaz, Role of estrogens in adipocyte development and function, *Exp. Biol. Med.* (Maywood) 229 (11) (2004) 1127–1135.
- [111] R. Okazaki, D. Inoue, M. Shibata, M. Saika, S. Kido, H. Ooka, et al., Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta, *Endocrinology* 143 (6) (2002) 2349–2356.
- [112] Z.C. Dang, R.L. van Bezooijen, M. Karperien, S.E. Papapoulos, C.W. Lowik, Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis, *J. Bone Miner. Res.* 17 (3) (2002) 394–405.
- [113] F. Lizcano, G. Guzman, Estrogen deficiency and the origin of obesity during menopause, *Biomed. Res. Int.* 2014 (2014) 757461.
- [114] F.A. Syed, M.J. Oursler, T.E. Hefferan, J.M. Peterson, B.L. Riggs, S. Khosla, Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women, *Osteoporos. Int.* 19 (9) (2008) 1323–1330.
- [115] G.K. Chan, G. Duque, Age-related bone loss: old bone, new facts, *Gerontology* 48 (2) (2002) 62–71.
- [116] A. Cohen, E.M. Stein, R.R. Recker, J.M. Lappe, D.W. Dempster, H. Zhou, et al., Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study, *J. Clin. Endocrinol. Metab.* 98 (5) (2013) 1971–1981.
- [117] Y. Yang, X. Luo, X. Xie, F. Yan, G. Chen, W. Zhao, et al., Influences of teriparatide administration on marrow fat content in postmenopausal osteopenic women using MR spectroscopy, *Climacteric* 19 (3) (2016) 285–291.
- [118] P.J. Marie, Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology, *Mol. Interv.* 10 (5) (2010) 305–312.
- [119] C. Vidal, K. Gunaratnam, J. Tong, G. Duque, Biochemical changes induced by strontium ranelate in differentiating adipocytes, *Biochimie* 95 (4) (2013) 793–798.
- [120] C. Fournier, A. Perrier, M. Thomas, N. Laroche, V. Dumas, A. Rattner, et al., Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells, *Bone* 50 (2) (2012) 499–509.
- [121] Z. Saidak, E. Hay, C. Marty, A. Barbara, P.J. Marie, Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc3/Maf and Wnt signaling, *Aging Cell* 11 (3) (2012) 467–474.
- [122] I.M. Conboy, M.J. Conboy, J. Rebo, Systemic problems: a perspective on stem cell aging and rejuvenation, *Aging (Albany NY)* 7 (10) (2015) 754–765.

- [123] Y. Zhang, J. Shao, Z. Wang, T. Yang, S. Liu, Y. Liu, et al., Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma, *Gene* 557 (2) (2015) 209–214.
- [124] Q. Lu, M.L. Tu, C.J. Li, L. Zhang, T.J. Jiang, T. Liu, et al., GDF11 inhibits bone formation by activating Smad2/3 in bone marrow mesenchymal stem cells, *Calcif. Tissue Int.* 99 (5) (2016) 500–509.
- [125] D. Moseti, A. Regassa, W.K. Kim, Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules, *Int. J. Mol. Sci.* 17 (1) (2016).
- [126] S. Rayalam, M.A. Della-Fera, C.A. Baile, Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis, *Mol. Nutr. Food Res.* 55 (8) (2011) 1177–1185.
- [127] Z. Dai, Y. Li, L.D. Quarles, T. Song, W. Pan, H. Zhou, et al., Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation, *Phytomedicine* 14 (12) (2007) 806–814.
- [128] C.Y. Lai, J.Y. Yang, S. Rayalam, M.A. Della-Fera, S. Ambati, R.D. Lewis, et al., Preventing bone loss and weight gain with combinations of vitamin D and phytochemicals, *J. Med. Food* 14 (11) (2011) 1352–1362.
- [129] H. Liu, W. Li, X. Ge, S. Jia, B. Li, Coadministration of puerarin (low dose) and zinc attenuates bone loss and suppresses bone marrow adiposity in ovariectomized rats, *Life Sci.* 166 (2016) 20–26.
- [130] Z.W. Li, C.D. Piao, H.H. Sun, X.S. Ren, Y.S. Bai, Asiatic acid inhibits adipogenic differentiation of bone marrow stromal cells, *Cell Biochem. Biophys.* 68 (2) (2014) 437–442.
- [131] Y. Xiong, K. Walker, X. Min, C. Hale, T. Tran, R. Komorowski, et al., Long-acting MIC-1/GDF15 molecules to treat obesity: evidence from mice to monkeys, *Sci. Transl. Med.* 9 (412) (2017).
- [132] S. Lee, J.R. Park, M.S. Seo, K.H. Roh, S.B. Park, J.W. Hwang, et al., Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells, *Cell Prolif.* 42 (6) (2009) 711–720.
- [133] C.H. Ko, W.S. Siu, H.L. Wong, W.T. Shum, K.P. Fung, C.B. San Lau, et al., Pro-bone and antifat effects of green tea and its polyphenol, epigallocatechin, in rat mesenchymal stem cells in vitro, *J. Agric. Food Chem.* 59 (18) (2011) 9870–9876.
- [134] M.J. Claesson, I.B. Jeffery, S. Conde, S.E. Power, E.M. O'Connor, S. Cusack, et al., Gut microbiota composition correlates with diet and health in the elderly, *Nature* 488 (7410) (2012) 178–184.
- [135] S. Dato, G. Rose, P. Crocco, D. Monti, P. Garagnani, C. Franceschi, et al., The genetics of human longevity: an intricacy of genes, environment, culture and microbiome, *Mech. Ageing Dev.* 165 (Pt B) (2017) 147–155.
- [136] E. Biagi, C. Franceschi, S. Rampelli, M. Severgnini, R. Ostan, S. Turrioni, et al., Gut microbiota and extreme longevity, *Curr. Biol.* 26 (11) (2016) 1480–1485.
- [137] C. Ohlsson, K. Sjogren, Effects of the gut microbiota on bone mass, *Trends Endocrinol. Metab.* 26 (2) (2015) 69–74.
- [138] J. Yan, J.W. Herzog, K. Tsang, C.A. Brennan, M.A. Bower, W.S. Garrett, et al., Gut microbiota induce IGF-1 and promote bone formation and growth, *Proc. Natl. Acad. Sci. U. S. A.* 113 (47) (2016) (E7554–E63).
- [139] E. Xiao, L. He, Q. Wu, J. Li, Y. He, L. Zhao, et al., Microbiota regulates bone marrow mesenchymal stem cell lineage differentiation and immunomodulation, *Stem Cell Res Ther* 8 (1) (2017) 213.
- [140] M. Ukita, T. Yamaguchi, N. Ohata, M. Tamura, Sclerostin enhances adipocyte differentiation in 3T3-L1 cells, *J. Cell. Biochem.* 117 (6) (2016) 1419–1428.
- [141] P.M. Chavassieux, M.E. Arlot, J.P. Roux, N. Portero, A. Daifotis, A.J. Yates, et al., Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies, *J. Bone Miner. Res.* 15 (4) (2000) 754–762.
- [142] F. Atashi, A. Modarressi, M.S. Pepper, The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review, *Stem Cells Dev.* 24 (10) (2015) 1150–1163.